Nanjing Miracle Biotechnology Co., Ltd.
Clinical trials sponsored by Nanjing Miracle Biotechnology Co., Ltd., explained in plain language.
-
A phase i, Single-Arm, Open-Label clinical study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CHT101 injection in subjects with Relapsed/Refractory T-Cell and B-Cell hematological malignancies
Not yet recruitingPrimary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of subjects with CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. P…
Phase 1 • Sponsor: Nanjing Miracle Biotechnology Co., Ltd.
Last updated Sep 09, 2026 16:00 UTC
-
A phase i, Single-Arm, Open-Label study to evaluate the safety, pharmacokinetics and preliminary efficacy of CHT101 injection in subjects with Relapsed/Refractory T-Cell and B-Cell hematological malignancies
Not yet recruitingPrimary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of anti-CD70 chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. Secondary Objective…
Phase 1 • Sponsor: Nanjing Miracle Biotechnology Co., Ltd.
Last updated Sep 09, 2026 16:00 UTC